Neonatal SectionNeonatal Plasma Transfusion: An Evidence-Based Review
Section snippets
Clinical Scenario
An extremely premature growth–restricted infant at 27 weeks' gestation weighing 500 g was delivered after a planned cesarean birth for suspected fetal compromise. She is admitted to the neonatal intensive care unit (NICU) and routine admission blood tests reveal that the prothrombin time (PT) and the activated partial thromboplastin time (aPTT) are elevated outside the reference ranges provided by the laboratory. The attending neonatologist requests plasma from the Blood Blank to prevent an
Background
Up to 15% of neonates admitted to the NICU are transfused with plasma when all birth weights and gestational ages are included [2], [3], [4]. Several clinical scenarios for plasma transfusion exist and are repeatedly identified in audits. Reasons given by health care professionals to support administration of neonatal plasma transfusion commonly include hypovolemia, bleeding with abnormal coagulation test results, abnormal coagulation test results without bleeding, intraoperative bleeding,
Plasma for Neonatal Transfusion
Fresh-frozen plasma is human donor plasma frozen within a short specified period after collection (often 8 hours) and then stored at a defined temperature, typically at −30°C. Plasma frozen at slightly later intervals (typically up to 24 hours) after collection is referred to as FP24. After thawing, although diluted with citrate anticoagulant, plasma contains near normal levels of many plasma proteins, including procoagulant and inhibitory components of the coagulation cascades, acute-phase
Reported Indications for Use of Plasma in Neonates
In neonatal practice, plasma is predominantly given to reduce perceived bleeding risk (prophylaxis) in nonbleeding patients. However, it should be accepted that all critically ill neonates might display some features of bleeding risk, for example, oozing at sites of venepuncture. Other usages include as a volume expander, bleeding with abnormal coagulation test results, intraoperative bleeding, sepsis, partial exchange for polycythemia, and exchange transfusions.
Potential Complications of Plasma Use in Neonates
Use of plasma is not without risks and can lead to transfusion-related acute lung injury, transfusion-related volume overload, febrile reactions, and hemolysis [16], all likely underrecognized and underreported in neonates. There is a reported association between plasma use and thrombotic events in neonatal [17] and pediatric [18] patients. Maruyama et al [17] in a single institutional study found an adjusted odd ratio of 5.88 for venous thrombosis in neonates who received greater than 50 mL/kg
Limitations of Coagulopathy Tests in Neonates
As part of a review of plasma use in neonates, it is important to acknowledge the limitations of coagulopathy tests in neonates. There remains an assumption that coagulation tests predict future bleeding; however, there are no studies that show at what level PT and international normalized ratio (INR) a neonate is at increased risk for bleeding. Several studies in neonates have found that routine admission coagulation tests lead to increased use of plasma but no impact on clinically significant
Search Strategy
To provide a comprehensive overview of the current evidence base for the use of plasma in neonates, a literature review was undertaken (Appendix A). The results of this review were used to inform this article and individual study characteristics are available in Table 1, Table 2.
What Is the Current Evidence to Define Use of Plasma in Neonates?
This review of the current literature revealed a limited number of studies (Appendix A, Fig. A1) providing relatively low levels of evidence to guide plasma use in neonates (Table 1, Table 2).
Commentary
The studies of the highest level of evidence, namely the systematic reviews, are limited by the quality of the studies that inform them [20], [22]. The best-designed and highest-quality study from the NNNI group showed that prophylactic plasma use had no impact on severe cranial ultrasound abnormalities and/or mortality. This study is probably the best guidance health care professionals have on the use of prophylactic plasma use in the NICU. However, because it was published in 1996, it is
Critical Analysis of the Clinical Scenario
How do we respond to previous clinical scenario? At a first level, we recognize the limitations of the tests to provide prediction of bleeding risk [9] and then we recognize the overall pattern of results in clinical trials, although few in number, to indicate very little likelihood of benefit of plasma use as (routine) prophylaxis, certainly at the doses frequently used. It, therefore, seems appropriate in this clinical case to challenge the request for plasma. Careful consideration of the
Gaps in Knowledge and Research Priorities
Research priority 1
The development of more accurate tests to define hemostatic problems in neonates is required and to link these with clinically important outcomes. It could be argued that these tests need to be evaluated before planning larger clinical trials to allow for a better understanding of the potential need for plasma and to identify key outcomes. In addition, use of a bleeding assessment tool in such trials would allow for standardization of recording of bleeding for clinical
Recommendations
With the limited evidence available to inform the use of plasma in neonates, it is challenging to make definitive recommendations. However, health care professionals still require guidance for its use and the following are provided acknowledging the limited evidence they are based upon:
- 1.
Routine admission coagulation screening is inappropriate because results are difficult to interpret in neonates and routine testing may lead to increased transfusion of plasma without benefit [19] (level III-2
Conclusion
This review of the evidence for use of plasma in neonates reveals its significant limitations to inform clinical practice, both in prophylactic and in therapeutic use. Currently available investigative tests do not accurately allow health care professionals to identify which neonates are at highest risk for bleeding or which will potentially benefit (if at all) from plasma transfusion. For such a commonly used blood product in the NICU, these are sobering findings. The previously outlined
References (37)
- et al.
A survey of Canadian neonatal blood transfusion practices
Transfus Sci
(1997) - et al.
Clinical use of fresh-frozen plasma in neonatal intensive care unit
Transfus Apher Sci
(2012) - et al.
Development of the human coagulation system in the healthy premature infant
Blood
(1988) Fresh frozen plasma: the most commonly prescribed hemostatic agent
J Thromb Haemost
(2013)- et al.
Controlled study of treatment for disseminated intravascular coagulation in the neonate
J Pediatr
(1982) - et al.
Fresh frozen plasma reduces thrombin formation in newborn infants
J Thromb Haemost
(2003) A propensity to bleed
Lancet Haematol
(2016)- et al.
Why do doctors use treatments that do not work?
BMJ
(2004) - et al.
Fresh frozen plasma use in the NICU: a prospective, observational, multicentred study
Arch Dis Child Fetal Neonatal Ed
(2014) - et al.
Temporal changes in blood product usage in preterm neonates born at less than 30 weeks' gestation in Canada
Transfusion
(2015)
Fresh frozen plasma and recombinant factor VIIa use in neonates
J Pediatr Hematol Oncol
Current transfusion practices for platelets and fresh, frozen plasma in UK tertiary level neonatal units
Acta Paediatr Suppl
The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children
Transfusion
Interpretation of clotting tests in the neonate
Arch Dis Child Fetal Neonatal Ed
Development of the human coagulation system in the full-term infant
Blood
A novel approach to standardised recording of bleeding in a high risk neonatal population
Arch Dis Child Fetal Neonatal Ed
Intraventricular hemorrhage in premature infants: mechanism of disease
Pediatr Res
Update on the use of pathogen-reduced human plasma and platelet concentrates
Br J Haematol
Cited by (26)
Neonatal Transfusion
2023, Avery's Diseases of the NewbornNew insights into neonatal hemostasis
2022, Thrombosis UpdateCitation Excerpt :However, in a cohort of 116 premature newborns (median gestational age 27.7 weeks), whose day one aPTT and PT were prolonged as compared to term newborns, the prolongation of clotting times was not associated with IVH [16]. Thus, there seems to be no role for prophylactic plasma transfusion to prevent intraventricular hemorrhage [17]. Mean platelet counts among term and preterm newborns are within the normal range for adults.
Variation in Neonatal Transfusion Practice
2021, Journal of PediatricsNeonatal Platelet Transfusions: Starting Again
2021, Transfusion Medicine ReviewsCitation Excerpt :There have been many comprehensive review articles about neonatal thrombocytopenia and platelet transfusion over the last two decades [1-12].
Closing the evidence to practice gap in neonatal transfusion medicine
2021, Seminars in Fetal and Neonatal MedicineCitation Excerpt :We remain in need of better diagnostic testing to identify which neonates would benefit most from plasma transfusion [21]. Our recommendation is to use plasma when active bleeding is present or before invasive procedures in those neonates with a risk of significant bleeding and who have an abnormal coagulation profile (defined as a prothrombin time or an activated partial thromboplastin time significantly above the normal gestational and postnatal age-related reference range) [20,21]. Other products used in the CNN database study included albumin at 915 (6%) and cryoprecipitate at 302 (2%) of 14 868 eligible neonates receiving at least one transfusion [2].
Procoagulant imbalance in preterm neonates detected by thrombin generation procedures
2020, Thrombosis ResearchCitation Excerpt :Such practice is not supported by current guidelines on the neonatal use of blood products [5] and is associated with increased mortality [4]. In addition to specific arguments that can be advocated against the inappropriate use of FFP [6,7], there are others that deserve consideration. Although there are reference intervals for PT and APTT in preterm newborns [8–10], they are hardly generalizable because of the between-reagent variability for PT and APTT results.
Conflict of interest: The authors have no conflicts of interests to declare.